Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).

Hiroyuki AraiTakashi TsudaYu SunakawaMototsugu ShimokawaKohei AkiyoshiShinya TokunagaHirokazu ShojiKenji KuniedaMasahito KotakaToshihiko MatsumotoYusuke NagataTakuro MizukamiFumitaka MizukiKathleen D DanenbergNarikazu BokuTakako Eguchi Nakajima

Published in: Cancer medicine (2024)

Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities.

Keyphrases

metastatic colorectal cancer
wild type
early onset
clinical trial
open label
radiation therapy
study protocol
placebo controlled
smoking cessation
double blind